Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure
Source: View publication →
In self-identified Black patients with advanced heart failure, the addition of a fixed-dose combination of isosorbide dinitrate and hydralazine to standard neurohormonal blockade significantly improved a composite metric of survival, hospitalizations, and quality of life.
Key Findings
Study Design
Study Limitations
Clinical Significance
A-HeFT established fixed-dose isosorbide dinitrate and hydralazine as a Class I guideline recommendation for self-identified Black patients with NYHA class III-IV heart failure with reduced ejection fraction who remain symptomatic despite optimal medical therapy. The trial successfully demonstrated that addressing distinct pathophysiological mechanisms—specifically nitric oxide depletion and increased oxidative stress—can yield substantial morbidity and mortality benefits.
Historical Context
Prior subgroup analyses from the V-HeFT I and II trials in the 1980s and 1990s suggested that Black patients might derive a disproportionate benefit from vasodilator therapy with hydralazine and isosorbide dinitrate, particularly since they frequently exhibited less robust clinical responses to standard ACE inhibitors. The A-HeFT trial was explicitly designed to test this hypothesis prospectively. Following its publication, the FDA approved the fixed-dose combination (BiDil) specifically for self-identified Black patients, marking a contentious milestone as the first race-specific drug indication in modern medicine and sparking intense debate over pharmacogenomics and the use of race in medical research.
Guided Discussion
High-yield insights from every perspective
What is the pathophysiologic rationale for combining hydralazine with isosorbide dinitrate, particularly regarding endothelial function and oxidative stress?
Key Response
Isosorbide dinitrate acts as a nitric oxide (NO) donor, promoting venodilation and reducing preload. Hydralazine acts as an arterial vasodilator to reduce afterload, but crucially, it also functions as an antioxidant. By reducing oxidative stress, hydralazine prevents the rapid degradation of NO, creating a synergistic effect that is especially beneficial in pathophysiological states where endogenous NO bioavailability is impaired.
In clinical practice, what are the most common adverse effects of the hydralazine/isosorbide dinitrate combination that limit patient adherence, and how should a clinician manage them?
Key Response
The combination frequently causes headaches, dizziness, and gastrointestinal distress, leading to high discontinuation rates. Clinicians must actively manage this by starting at lower doses, titrating slowly, and educating patients that the headaches are often transient and can be managed with over-the-counter analgesics initially to maintain adherence to this mortality-reducing therapy.
Given the success of A-HeFT in Black patients, how should a heart failure specialist approach the use of hydralazine/isosorbide dinitrate in non-Black patients with HFrEF?
Key Response
While A-HeFT focused on self-identified Black patients due to retrospective signals from V-HeFT I/II, hydralazine/ISDN is frequently used off-label in non-Black patients who are intolerant to ACEi/ARB/ARNI (e.g., due to severe renal dysfunction or hyperkalemia) or who remain symptomatic despite guideline-directed medical therapy. Fellows must weigh the lack of targeted prospective trial data in this demographic against the physiologic rationale and need for salvage therapy.
The A-HeFT trial introduced the concept of race-based therapeutics in cardiology. As an attending, how do you contextualize and teach the limitations of using a social construct like self-identified race as a proxy for pharmacogenomics?
Key Response
Race is a social, not biological, construct. Using it as a proxy for reduced nitric oxide bioavailability or specific genetic variants is imprecise. Attendings must teach trainees to recognize the historical significance of A-HeFTs mortality benefit while advocating for a transition toward precision medicine that targets actual physiological markers or genetic profiles rather than relying on broad racial categories.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The A-HeFT trial was terminated early due to a significant mortality benefit. What are the statistical and epidemiological risks of early trial termination for benefit, and how might it affect the estimation of the true treatment effect size?
Key Response
Early termination for benefit often leads to an overestimation of the treatment effect, a phenomenon known as the random high or regression to the mean. Researchers must critically evaluate whether the stopping rules (e.g., OBrien-Fleming boundaries) were appropriately conservative, and consider how early stopping limits the statistical power of secondary endpoints and the collection of long-term safety data.
If reviewing the A-HeFT manuscript today, how would you critically appraise the use of a composite primary endpoint that combines mortality, first heart failure hospitalization, and change in quality of life score?
Key Response
Editors must scrutinize composite endpoints to ensure the components have similar clinical importance and directionality of effect. Mixing a hard objective endpoint like mortality with a softer subjective one like a quality of life score can obscure true effects or drive a positive trial purely through the softer metric. Reviewers must demand a clear breakdown of each component to ensure there is no masking or endpoint creep.
Based on the A-HeFT trial, what is the current ACC/AHA/HFSA guideline recommendation for the use of hydralazine and isosorbide dinitrate in self-identified African American patients, and how does modern background therapy complicate this?
Key Response
Current guidelines give a Class 1 recommendation for adding hydralazine and ISDN to self-identified African American patients with NYHA class III-IV HFrEF receiving optimal medical therapy. The committee must consider that optimal therapy during A-HeFT did not include ARNIs or SGLT2 inhibitors. Updating guidelines requires evaluating whether the absolute benefit of this combination persists on top of modern, more robust quadruple therapy.
Clinical Landscape
Noteworthy Related Trials
V-HeFT I
Tested
Hydralazine plus isosorbide dinitrate
Population
Men with impaired left ventricular function and heart failure
Comparator
Placebo or prazosin
Endpoint
All-cause mortality
V-HeFT II
Tested
Enalapril
Population
Men with chronic heart failure taking digoxin and diuretics
Comparator
Hydralazine plus isosorbide dinitrate
Endpoint
All-cause mortality
SOLVD-Treatment Trial
Tested
Enalapril
Population
Patients with symptomatic heart failure and an ejection fraction of 35 percent or less
Comparator
Placebo
Endpoint
All-cause mortality
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis